Innate Pharma S.A. develops clinical-stage cancer immunotherapies based on antibody engineering and target identification. Company news commonly covers its next-generation antibody therapeutics portfolio, including IPH4502, a Nectin-4 antibody-drug conjugate for solid tumors; lacutamab, an anti-KIR3DL2 antibody for cutaneous and peripheral T-cell lymphomas; monalizumab, an anti-NKG2A antibody developed with AstraZeneca for non-small cell lung cancer; and IPH5201, an anti-CD39 antibody studied in non-small cell lung cancer.
Updates also address collaborations with biopharmaceutical partners such as Sanofi and AstraZeneca, oncology conference presentations, business updates, annual meeting matters, share-count and voting-right disclosures, and annual reporting under French and U.S. public-company requirements.
Innate Pharma (IPHA) presented initial Phase 1 results for its investigational cancer drug IPH4502 in patients with advanced solid tumors. The dose-escalation study enrolled 76 patients. At the maximum tolerated dose of 3.6 mg/kg every three weeks, the objective response rate was 33% (2/6) in non-urothelial tumors. Among 19 patients with urothelial cancer previously treated with enfortumab vedotin, three had partial responses at lower doses: one confirmed and two unconfirmed. None received the maximum tolerated dose.
Stomatitis (mouth inflammation) was the only reported side effect that limited dosing. Grade 3 or higher adverse events emerging during treatment occurred in 43.4% of patients. Innate is starting dose optimization in previously treated urothelial cancer, with the first patient planned for the first half of 2027, to assess safety and activity at upper dose levels and select a recommended Phase 2 regimen.
Innate Pharma (Nasdaq: IPHA) will host an in-person and virtual event on IPH4502 Phase 1 data on November 18, 2026. The event begins at 11:00 a.m. ET / 4:00 p.m. GMT at IET London, Savoy Place.
Professor Yohann Loriot of Gustave Roussy will join management to discuss safety, pharmacokinetics—the drug's behavior in the body—and antitumor activity from the dose-escalation study. Presentations will also cover the urothelial cancer treatment landscape and next steps in IPH4502's clinical development, followed by a live question-and-answer session. A replay will be available in the investors section of Innate Pharma's website.
Innate Pharma (Nasdaq: IPHA) reported a third-quarter business update with cash, cash equivalents and financial assets of €96.8 million. The September 30, 2026 balance includes proceeds from the Sobi transaction and August share offering. Innate anticipates funding through the end of Q1 2028. Nine-month revenue was €3.4 million versus €2.3 million a year earlier; financial liabilities were €16.2 million.
IPH4502 Phase 1 dose-escalation enrollment is complete at 76 patients, with data presentation set for November 18, 2026. Innate expects first dosing in lacutamab’s Phase 3 TELLOMAK-3 trial in Q1 2027 and plans an FDA accelerated approval filing in Sézary syndrome in H2 2027, once that study is underway. AstraZeneca’s PACIFIC-9 readout is now expected in H1 2027 rather than H2 2026 because the study is event-driven. CFO Frédéric Lombard will leave December 31, 2026; a replacement search has begun.
Innate Pharma (IPHA) announced that AstraZeneca now expects the PACIFIC-9 Phase 3 trial’s high-level data readout in H1 2027. The previous expectation was the second half of 2026. The company attributed the revised timing to the study’s event-driven nature.
The AstraZeneca-led trial evaluates durvalumab combined with monalizumab or oleclumab in patients with unresectable Stage III non-small cell lung cancer, meaning cancer that cannot be surgically removed. Eligible patients have not progressed following platinum-based chemotherapy and radiation therapy. Enrollment is complete. Monalizumab is an anti-NKG2A antibody developed by Innate Pharma in collaboration with AstraZeneca. AstraZeneca obtained full oncology rights to monalizumab in October 2018 through a co-development and commercialisation agreement initiated in 2015.
Innate Pharma (Nasdaq: IPHA) announced that its executive team members will participate in two healthcare investor conferences in November 2026. The Stifel Healthcare Conference takes place November 10–12 in New York, with a fireside chat on November 10 at 2:00 p.m. ET / 8:00 p.m. CET. A live webcast and subsequent replay will be available through the company’s investor Events page. The Jefferies Global Healthcare Conference runs November 16–19 in London.
Innate Pharma (IPHA) will hold its third-quarter 2026 business and financial update conference call on November 5, 2026. The call begins at 2 p.m. CET / 8 a.m. ET, with members of senior management participating. A webcast replay will be available on the company website for 90 days following the event.
Innate Pharma (IPHA) reported first-half 2026 results and a new global partnership with Sobi for lacutamab, including a USD 75 million upfront payment following transaction closing on September 16, 2026.
The Sobi deal supports initiation of the TELLOMAK-3 Phase 3 CTCL study, with first patient expected in Q1 2027, and could bring up to USD 505 million in additional milestones plus tiered double-digit royalties. Innate also completed a €30 million private placement of 17,647,059 new shares and expects, together with the Sobi upfront payment, to extend its cash runway to the end of Q1 2028. As of June 30, 2026, cash, cash equivalents, short-term investments and financial assets were €21.4 million and financial liabilities were €20.2 million. Revenue and other income reached €5.7 million, while operating expenses fell to €24.7 million, driven by lower R&D and G&A costs.
Innate Pharma (IPHA) reports that its previously announced strategic partnership with Sobi is now effective after antitrust waiting periods expired and other closing conditions were met.
Completion of the transaction triggers a USD 75 million upfront payment to Innate and marks the initiation of the TELLOMAK-3 confirmatory Phase 3 study of lacutamab in cutaneous T-cell lymphoma, with first patient enrollment expected in Q1 2027. Under the agreement, Innate will conduct the TELLOMAK-3 trial, which is intended to support applications for full approvals in Sézary syndrome and mycosis fungoides in key jurisdictions. Sobi receives exclusive global commercialization rights to lacutamab upon potential accelerated approval and may assume full global development rights following positive Phase 3 results.
Innate Pharma (IPHA) will host a conference call and webcast on September 17, 2026 at 2:00 p.m. CEST / 8:00 a.m. EDT to present its first half 2026 business update.
The call will feature CEO Jonathan Dickinson, Chief Medical Officer Markus Jensen, Chief Operating Officer Yannis Morel and Chief Financial Officer Frédéric Lombard. Access links for the webcast and conference call are provided in the Investors section of Innate Pharma’s website. A replay of the webcast will be available on the company website for 90 days after the event.
Innate Pharma (Euronext Paris: IPH; Nasdaq: IPHA) will participate in the H.C. Wainwright 28th Annual Global Investment Conference in New York, United States, from September 14–16, 2026. Members of the executive team will join a fireside chat and hold one-on-one investor meetings.
The fireside chat is scheduled for September 14, 2026 at 4:30 PM EDT / 10:30 PM CEST, with a live webcast accessible via the Events page of the Investors section on Innate Pharma’s website and a replay available afterward. According to the company, Innate is a clinical-stage biotechnology group focused on next‑generation antibody therapeutics, including its proprietary ADC pipeline led by IPH4502 and partnered late‑stage assets lacutamab and monalizumab.